SCHEMBL23969824

SCHEMBL23969824

Cc1c(N)c(Cl)c(C(C)C)c(Cl)c1Cl

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24599603 0.86 ALDH1A1 (0.33) ALDH1A1GAAMAPT
SCHEMBL23867814 0.81
SCHEMBL23969790 0.81
SCHEMBL23848391 0.80 ALDH1A1 (0.31) ALDH1A1GAAMAPT
SCHEMBL23848382 0.80
SCHEMBL23848389 0.80 ALDH1A1 (0.31) ALDH1A1GAAMAPT
SCHEMBL23569166 0.80
SCHEMBL23848380 0.79
SCHEMBL23867678 0.76
SCHEMBL28424298 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787811-B2 KRAS mutant protein inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-10-17 US disclosed
US-20230011726-A1 KRAS mutant protein inhibitors JACOBIO PHARMACEUTICALS CO LTD (CN) 2023-01-12 US disclosed
US-11384087-B1 2022-07-12 US disclosed
US-20220213109-A1 KRAS mutant protein inhibitors JACOBIO PHARMACEUTICALS CO LTD (CN) 2022-07-07 US disclosed
US-11345701-B1 KRAS mutant protein inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-05-31 US disclosed
US-11161847-B2 KRAS mutant protein inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161847-B2 KRAS mutant protein inhibitors KRAS, NRAS, APC ALDH1A1 3827/4885GAA 2707/4885MAPT 2468/4885
US-20230011726-A1 KRAS mutant protein inhibitors KRAS, NRAS, APC ALDH1A1 3978/4885GAA 2859/4885MAPT 2472/4885
US-11384087-B1 KRAS, NRAS, APC ALDH1A1 3682/4885GAA 2346/4885MAPT 2730/4885
US-11345701-B1 KRAS mutant protein inhibitors KRAS, NRAS, APC ALDH1A1 3827/4885GAA 2707/4885MAPT 2468/4885
US-11787811-B2 KRAS mutant protein inhibitors KRAS, NRAS, APC ALDH1A1 3978/4885GAA 2859/4885MAPT 2472/4885
US-20220213109-A1 KRAS mutant protein inhibitors KRAS, NRAS, APC ALDH1A1 3978/4885GAA 2859/4885MAPT 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.